论文部分内容阅读
目的:观察复可托对恶性肿瘤患者免疫功能、生活质量的影响。方法:将117例恶性肿瘤患者随机分为治疗组(60例)和对照组(57例),对照组给予最佳支持治疗,治疗组在此基础上给予复可托治疗连续6个月。观察并比较两组治疗前、治疗后2、4、6个月的外周血T淋巴细胞亚群的变化及生活质量评分。结果:治疗2个月后,治疗组CD3~+、CD4~+细胞比例、CD4~+/CD8~+较对照组显著升高(P<0.05),CD8~+细胞比例较治疗前下降,但差异无统计学意义(P>0.05);治疗4、6个月后,治疗组CD3~+、CD4~+细胞比例、CD4~+/CD8~+升高,CD8~+细胞比例下降,差异有统计学意义(P<0.05);治疗6个月后,治疗组的KPS评分改善有效率和体重改善有效率均显著高于对照组,差异有统计学意义(P<0.05)。两组均未见明显不良反应发生。结论:复可托能纠正恶性肿瘤患者外周血T淋巴细胞亚群功能紊乱,同时明显改善患者生活质量,减少体重下降,且安全性高。
Objective: To observe the influence of complex trust on immune function and quality of life in patients with malignant tumor. Methods: A total of 117 patients with malignant tumor were randomly divided into treatment group (60 cases) and control group (57 cases). The control group was given the best supportive therapy. The treatment group was treated with metoclophorone for 6 months continuously. The changes of T lymphocyte subsets and quality of life in two groups before treatment, 2, 4 and 6 months after treatment were observed and compared. Results: After treated for 2 months, the proportion of CD3 ~ +, CD4 ~ + cells and CD4 ~ + / CD8 ~ + in the treatment group were significantly higher than those in the control group (P <0.05) The difference was not statistically significant (P> 0.05). After treatment for 4 and 6 months, the proportion of CD3 ~ + and CD4 ~ + cells, CD4 ~ + / CD8 ~ + increased and the proportion of CD8 ~ + cells decreased Statistical significance (P <0.05). After 6 months of treatment, KPS scores of treatment group were significantly improved and effective rate of body weight improvement was higher than that of control group (P <0.05). No obvious adverse reactions occurred in both groups. Conclusions: FITO can correct the dysfunction of T lymphocyte subsets in peripheral blood of patients with malignant tumor, meanwhile, it can obviously improve the quality of life of patients, reduce the weight loss and have high safety.